New hope for hard-to-treat ovarian cancer: targeted drug shows promise in early trial

This study tests a drug called sacituzumab govitecan in 20 people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The drug works like a guided missile, delivering chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or disappear. Participants must have measurable disease and provide a tumor sample for testing.